At High End Marketplace, we take pride in curating the best cannabis products for our customers. One standout brand we carry is Sub X, short for Subdued Excitement. Known for their meticulous attention to detail and commitment to quality, Sub X has become a trusted name in Washington State’s cannabis scene.

A Legacy Rooted in Excellence

Sub X originates from Bellingham, Washington, a city affectionately known as “The City of Subdued Excitement.” This name perfectly reflects the brand’s ethos—delivering exceptional cannabis with a laid-back, Pacific Northwest vibe. With roots in underground cultivation, Sub X transitioned into the legal market with the passage of Washington’s Initiative 502, bringing decades of expertise to their craft.

Quality Above All

Every product from Sub X speaks to their dedication to quality. Their cannabis is cultivated in small batches in controlled indoor environments, allowing for precise care throughout the growth cycle. Each flower is hand-trimmed and cured to perfection, ensuring the preservation of terpenes, potency, and flavor. Furthermore, Sub X conducts comprehensive testing for pesticides, terpenes, and cannabinoids, exceeding state-mandated standards. This meticulous process guarantees clean and potent cannabis that enthusiasts can trust.

Sustainable Practices for the Future

Sub X is deeply committed to sustainability, inspired by their connection to the Pacific Northwest’s natural beauty. They employ efficient growing methods designed to minimize resource consumption and reduce their carbon footprint. This eco-conscious approach not only benefits the environment but also aligns with the values of modern cannabis consumers.

Strains That Delight

Sub X offers an impressive array of strains, ranging from modern classics to unique in-house creations. Here are a few customer favorites:

• Hawaiian Dutch: A sativa-dominant strain with vibrant citrus and tropical flavors. Known for its uplifting effects, it’s perfect for a productive day.
• White Urkle: This indica-leaning hybrid combines the best traits of Purple Urkle and The White, offering a balanced high ideal for relaxation.
• Chem Cookies: An indica-dominant hybrid with a creative, euphoric essence. It’s a go-to choice for camping trips or unwinding in nature.

These strains showcase Sub X’s commitment to superior genetics and their ability to cater to a wide range of preferences and experiences.

Elevate Your Cannabis Experience

At High End Marketplace, we’re thrilled to bring Sub X’s exceptional products to our customers. Whether you’re a seasoned cannabis connoisseur or new to the scene, Sub X offers something for everyone. Their small-batch, artisan approach ensures a premium experience in every jar.

Explore our selection of Sub X products in-store or online at High End Marketplace. With a reputation built on quality, sustainability, and innovation, Sub X continues to set the standard for cannabis excellence in Washington State. Don’t miss the opportunity to elevate your cannabis journey with one of the most respected brands in the industry.

For more information about Sub X, visit their official website: Subdued Excitement. Learn about their story, strains, and commitment to quality and sustainability—and see why they’re a favorite among cannabis enthusiasts.

On December 7, 2024, the Centers for Disease Control and Prevention (CDC) launched a new public awareness campaign aimed at educating young adults about the risks of combining cannabis and alcohol. This campaign is backed by recent studies indicating that using both substances simultaneously can significantly heighten impairment and increase long-term health risks.

Key Findings Driving the Campaign

A comprehensive study published earlier this year demonstrated that simultaneous consumption of cannabis and alcohol leads to higher blood THC levels, exacerbating psychoactive effects and slowing motor coordination. These effects can be particularly dangerous when engaging in activities such as driving. Learn more from the CDC.

Harm Reduction Strategies

The CDC’s initiative focuses on harm reduction, encouraging users to:

• Consume cannabis and alcohol responsibly, ideally not together.
• Understand the potential effects of each substance individually.
• Prioritize safety by avoiding impaired activities.

Industry Response

Cannabis advocacy groups and companies have expressed support for the campaign, highlighting the importance of fostering an informed consumer base. Educational outreach is seen as a vital step toward reducing stigma and promoting responsible use as legalization continues to expand. Explore additional insights on harm reduction.

Why This Matters

As cannabis becomes increasingly accessible, the responsibility to educate users on safe practices grows. Campaigns like this ensure that public health remains a priority, aligning with broader efforts to integrate cannabis into mainstream society responsibly.

Stay informed and explore further updates on cannabis policy, technology, and education as the industry continues to evolve.

The Drug Enforcement Administration (DEA) has introduced yet another delay in its consideration of rescheduling cannabis, pushing any substantive movement into 2025. This development has sparked disappointment among advocates, patients, and industry stakeholders who were hoping for a resolution this year. The proposed reclassification of cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA) was seen as a crucial step toward acknowledging its medical value and reducing restrictions on research and industry operations. However, the agency’s handling of procedural matters has left reform in limbo yet again.

The Context: Rescheduling Proposal

In March 2024, the Department of Justice recommended rescheduling cannabis to Schedule III following a scientific review by the Department of Health and Human Services (HHS). This change would represent a significant shift from the current Schedule I status, which equates cannabis with substances like heroin, deemed to have no accepted medical use and a high potential for abuse. Moving cannabis to Schedule III would acknowledge its medical utility and ease certain federal restrictions, such as those impacting tax deductions for cannabis businesses under IRS Code 280E.

Delays and Bureaucratic Challenges

The DEA had scheduled a hearing for December 2024 to gather expert input on the proposed rescheduling. However, procedural issues arose when the agency failed to adequately prepare its witness list, prompting a DEA administrative law judge to postpone the testimony phase until early 2025. This delay effectively pushes any final decision into the next presidential administration, raising uncertainty about whether the current momentum for reform will continue.

Critics argue that the DEA’s actions reflect ongoing skepticism and reluctance to address cannabis reform meaningfully. By introducing procedural hurdles and postponing substantive hearings, the agency has prolonged a process that many believe should have been expedited, especially given the widespread support for rescheduling across the scientific and medical communities.

Implications for the Cannabis Industry and Patients

The delay impacts not only the burgeoning cannabis industry but also patients relying on medical cannabis. While rescheduling would not legalize cannabis federally, it could pave the way for enhanced research opportunities, improved access, and reduced regulatory burdens for businesses. Additionally, moving cannabis to Schedule III would symbolize progress in destigmatizing its use for medical and therapeutic purposes.

However, opponents of rescheduling caution that it could introduce new regulatory complexities without fully addressing the systemic issues caused by federal prohibition. For instance, the reclassification would still subject cannabis to certain criminal prohibitions and international treaty obligations, leaving gaps in federal and state policy alignment.

What’s Next?

The rescheduling debate will continue into 2025, with the DEA’s next steps likely influenced by the incoming administration. Meanwhile, advocates are urging the agency to prioritize scientific findings and public health over bureaucratic inertia. Stakeholders are encouraged to participate in the ongoing public discourse, emphasizing the need for policies that reflect modern understanding of cannabis and its benefits.

For now, the cannabis community must navigate this uncertain landscape while advocating for comprehensive reform that extends beyond rescheduling to address federal legalization and decriminalization.